BioSpace News Archive

Osler Diagnostics, a medical diagnostic company aiming to transform global healthcare by providing lab-quality diagnostic testing to anyone, anywhere, at any time, announced that it has raised $85 million in a Series C financing.

Apros Therapeutics, Inc. announced that they will present interim pharmacokinetic and pharmacodynamic Phase 1 clinical data for APR003 at the 2022 Society for Immunotherapy of Cancer Annual Meeting to be held November 8-12th in Boston, MA.

Innate Pharma SA, announced that the Company will hold a conference call on Monday, November 14, 2022, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2022.

KalVista Pharmaceuticals, Inc. announced it will participate in a fireside chat at the following investor conferences: Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:50 p.m. EST Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 8:35 a.m. GMT

Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the third quarter 2022 and provide a business update on Monday, November 14, 2022.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, after the close of market.

Kimball Electronics, Inc. announced financial results for the first quarter ended September 30, 2022.

Geron Corporation announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET.

CinCor Pharma, Inc. (“CinCor”) announced that detailed results from the Phase 2 BrigHtn trial evaluating the safety and efficacy of baxdrostat in treatment-resistant hypertension were published online today in the New England Journal of Medicine.

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial.